Payment overview · 2025
General Payments
$326.91
19 reported records · 7 companies
Healthcare provider profile · identity verified
Steven J Vacek, MD
Allopathic & Osteopathic Physicians|Family Medicine · GLEN ROSE, TX · NPI 1164473666
Verified facts
What the public records show
CMS Open Payments records show Steven J Vacek, MD received $326.91 in general payments during 2025 across 19 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $82.87 | 25.4% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $72.02 | 22.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.57 | 21.6% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.41 | 11.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.53 | 9.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.28 | 5.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.23 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $326.91 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.57 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $67.39 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $55.01 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.53 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.53 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 46 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
131 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 400 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 393 | 122 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 273 | 59 |
| Gabapentin | Gabapentin | 260 | 63 |
| Lisinopril | Lisinopril | 224 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 210 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 207 | 69 |
| Tramadol Hcl | Tramadol Hcl | 203 | 50 |
| Alprazolam | Alprazolam | 197 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 63 |
| Omeprazole | Omeprazole | 163 | 52 |
| Metformin Hcl | Metformin Hcl | 152 | 46 |
| Losartan Potassium | Losartan Potassium | 138 | 45 |
| Simvastatin | Simvastatin | 138 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 135 | 44 |
| Eliquis | Apixaban | 131 | 30 |
| Furosemide | Furosemide | 131 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 126 | 34 |
| Montelukast Sodium | Montelukast Sodium | 123 | 37 |
| Meloxicam | Meloxicam | 118 | 43 |
| Potassium Chloride | Potassium Chloride | 94 | 26 |
| Trazodone Hcl | Trazodone Hcl | 94 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 24 |
| Sertraline Hcl | Sertraline Hcl | 88 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 80 | 24 |
| Temazepam | Temazepam | 80 | 17 |
| Diazepam | Diazepam | 79 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 25 |
| Synthroid | Levothyroxine Sodium | 75 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 29 |
| Carvedilol | Carvedilol | 73 | 25 |
| Alendronate Sodium | Alendronate Sodium | 72 | 19 |
| Lorazepam | Lorazepam | 72 | 20 |
| Mirtazapine | Mirtazapine | 70 | 14 |
| Pregabalin | Pregabalin | 69 | 24 |
| Memantine Hcl | Memantine Hcl | 68 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 67 | 19 |
| Allopurinol | Allopurinol | 65 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 21 |
| Bupropion Xl | Bupropion Hcl | 59 | 16 |
| Donepezil Hcl | Donepezil Hcl | 58 | suppressed |
| Celecoxib | Celecoxib | 57 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 57 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 13 |
| Finasteride | Finasteride | 52 | 18 |
| Spironolactone | Spironolactone | 48 | 17 |
| Ozempic | Semaglutide | 46 | 13 |
| Buspirone Hcl | Buspirone Hcl | 45 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 18 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 42 | 13 |
| Jardiance | Empagliflozin | 41 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 40 | 24 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 13 |
| Atenolol | Atenolol | 37 | 13 |
| Prednisone | Prednisone | 37 | 14 |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | suppressed |
| Methocarbamol | Methocarbamol | 34 | 11 |
| Clonidine Hcl | Clonidine Hcl | 33 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 28 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 32 | suppressed |
| Famotidine | Famotidine | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | 11 |
| Methylprednisolone | Methylprednisolone | 31 | 28 |
| Linzess | Linaclotide | 30 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Eszopiclone | Eszopiclone | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 26 |
| Glimepiride | Glimepiride | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Paliperidone Er | Paliperidone | 24 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 23 | 23 |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Rybelsus | Semaglutide | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Silodosin | Silodosin | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Lyrica | Pregabalin | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Lovastatin | Lovastatin | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $326.91 · 19 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, COMIRNATY, Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE, MOUNJARO, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error